Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Odanacatib on the Single Dose Pharmacokinetics and Pharmacodynamics of Warfarin after Administration in Healthy Postmenopausal Female Subjects.

Next Previous
Search
Trial Profile

Effect of Odanacatib on the Single Dose Pharmacokinetics and Pharmacodynamics of Warfarin after Administration in Healthy Postmenopausal Female Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odanacatib (Primary) ; Warfarin (Primary)
  • Indications Postmenopausal osteoporosis; Thromboembolism
  • Focus Pharmacokinetics

Most Recent Events

  • 25 Mar 2013 New trial record
  • 09 Mar 2013 Primary endpoint 'Area-under-the-drug-concentration-time-curve' has been met.
  • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top